Carisma Therapeutics Presents Data from Phase I Clinical Trial of CT-0508, A HER2 Targeted CAR-Macrophage

November 12, 2021

PHILADELPHIA, November 12, 2021, 12:10 PM ET-- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today for the first time preliminary findings from the landmark Phase 1 multi-center clinical trial of CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric...

CARISMA Announces Multiple Abstracts Accepted for Presentation at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting

November 1, 2021

PHILADELPHIA, November 1, 2021 -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the acceptance of a late breaker abstract for oral presentation of its clinical study data and three pre-clinical study abstracts to be presented at the upcoming Society for...